Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges

Here, in a longitudinal cohort of 1245 hospital care workers and 146 nursing home residents, the authors find that a large inter-individual variation in anti-spike antibody levels after one dose of BNT162b2mRNA vaccine is partially explained by age, sex, previous exposure, and treatments, while the...

Full description

Bibliographic Details
Main Authors: João Faro-Viana, Marie-Louise Bergman, Lígia A. Gonçalves, Nádia Duarte, Teresa P. Coutinho, Patrícia C. Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro, Ana Brennand, Lindsay Kosack, Onome Akpogheneta, João M. Figueira, Conceição Cardoso, Ana M. Casaca, Paula M. Alves, Telmo Nunes, Carlos Penha-Gonçalves, Jocelyne Demengeot
Format: Article
Language:English
Published: Nature Portfolio 2022-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-27761-z
Description
Summary:Here, in a longitudinal cohort of 1245 hospital care workers and 146 nursing home residents, the authors find that a large inter-individual variation in anti-spike antibody levels after one dose of BNT162b2mRNA vaccine is partially explained by age, sex, previous exposure, and treatments, while the 2nd dose is required to reach sero-conversion at the population level.
ISSN:2041-1723

Similar Items